Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
|Articles|June 17, 2015
Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer
Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.
Advertisement
Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.
Advertisement
Related to this article
Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI Breast Cancer Risk Models Guide Triage and Nurse-Led Patient Counseling
2
Sunvozertinib Now Available in US for Pretreated EGFR Exon 20+ NSCLC
3
What Oncology Nurses Need to Know About ADCs in Breast Cancer
4
Male Breast Cancer: Warning Signs, Biology, and Genetic Testing
5